RECEPTOPHARM, INC.
PLANTATION, FLORIDA

ReceptoPharm, Inc. is a pioneering biopharmaceutical company focused on the discovery and development of therapeutic protein products aimed at preventing and treating viral, autoimmune, and neurological disorders in humans. Originally incorporated as Receptogen under Nevada law on June 4, 2001, the company transitioned to its current name, ReceptoPharm, in April 2003. Licensed to operate in Florida, ReceptoPharm's headquarters are based in Plantation, Florida. The company specializes in leveraging receptor-binding proteins found naturally for developing novel therapeutic agents and off-patent peptide technologies. This innovative approach concentrates on diseases such as multiple sclerosis (MS), adrenomyeloneuropathy (AMN), human immunodeficiency virus (HIV), myasthenia gravis (MG), rheumatoid arthritis (RA), and other pain-related disorders, offering the potential to deliver significant benefits to patients suffering from these conditions. In addition to its own product development initiatives, ReceptoPharm extends a comprehensive suite of contract services to support start-up and small biotechnology companies. These offerings encompass pre-production studies, contract manufacturing services, regulatory support for both U.S. and EU markets, as well as assistance with quality systems and GMP certification. The executive team is led by President Dale Ph.D. Vanderputten, alongside Director Erik J. Deitsch. The company maintains transparency in its operations through annual reports, the latest of which was issued on April 29, 2024. ReceptoPharm's official online presence can be accessed via their website at receptopharm.com.